Drugs / KW-2449
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00779480 | Jan 2009 → Apr 2010 | acute myeloid leukemia | Kyowa Kirin, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT00346632 | Jun 2006 → Apr 2008 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | Kyowa Kirin, Inc. | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KW-2449 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00779480 ↗ |
| Action | Inhibit | “sufficient to inhibit FLT3 autophosphorylation to less than 20% of its baseline” PMID 19029442 ↗ Nov 20084“Serine/threonine-protein kinase Aurora-A inhibitor” CHEMBL1908397 ↗ “Serine/threonine-protein kinase Aurora-B inhibitor” CHEMBL1908397 ↗ “Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL1908397 ↗ “Tyrosine-protein kinase ABL inhibitor” CHEMBL1908397 ↗ |
| Modality | Small molecule | — CHEMBL1908397 ↗ |
| Route | Oral | “Sequential ascending oral doses of KW-2449 given for 14 or 28 days” NCT00346632 ↗ |
| Target | ABL1 | “Tyrosine-protein kinase ABL inhibitor” CHEMBL1908397 ↗ |
| Target | AURKA | “Serine/threonine-protein kinase Aurora-A inhibitor” CHEMBL1908397 ↗ |
| Target | AURKB | “Serine/threonine-protein kinase Aurora-B inhibitor” CHEMBL1908397 ↗ |
| Target | FLT3 | “Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL1908397 ↗ |